Compare Freshworks Inc (FRSH) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs Mesoblast Limited — how do they compare? Freshworks Inc trades at $10.61 (market cap $2.93B), while Mesoblast Limited trades at $17.82 (market cap $2.31B). The key difference: Freshworks Inc is the larger of the two by market cap, and Mesoblast Limited is trading nearer its 52-week high, Freshworks Inc nearer its low. Which is the better fit depends on your goals.
| FRSH | MESO | |
|---|---|---|
Market Cap | $2.93B | $2.31B |
Sector | Technology | Technology |
52-Week High | $14.77 | $20.96 |
52-Week Low | $6.88 | $11.35 |
Enterprise Value | $2.19B | $2.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $10.88, up 3.92% with a bullish technical signal and strong revenue growth from $720M in 2024 to $839M in 2025. The company achieved profitability in 2025 with net income of $184M, reversing prior losses. Recent news highlights AI product launches and a key partnership with Vanquis, while analyst consensus is split evenly between Buy and Hold ratings.
The outlook is positive with accelerating revenue and a path to sustained profitability, though high EV/EBITDA of 51.08 suggests premium valuation. Risks include execution on AI initiatives and competitive pressure in SaaS. Wall Street sees 26-38% upside potential based on price targets, making FRSH an attractive growth story if margins expand as projected.
MESO is trading at $18.61, up 11.17% today, with strong technical momentum as moving averages signal bullish conditions. The company shows promising revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a -144.33% net income margin. Recent milestones include completing patient recruitment for a Phase 3 chronic low back pain trial and securing a $50 million non-dilutive facility.
The outlook is cautiously optimistic given strong analyst support (45% buy ratings) and commercial progress, but significant execution risks remain. Investors face high valuation multiples (P/S 30.52) and substantial cash burn despite reduced operating expenses. The stock's near-term direction will depend on clinical trial outcomes and revenue acceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
